AIM ImmunoTech Inc. (NYSEAM: AIM)
Health Care · Biotechnology · US
$0.17
-6.61% today · -93.5% 1Y
AIM ImmunoTech Inc. (NYSEAM: AIM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.12M and employs 19 people.
Over the last twelve months the share price has lost 93.5%, trading between 0.16 and 2.88.
Tweenvest scores AIM ImmunoTech Inc. across four factors: quality 35/100, value 43/100, growth 0/100. Its strongest factor is value.
AIM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.12M
- Revenue (TTM)
- $95.00K
- P/E
- —
- EPS
- -2.14
- Dividend yield
- —
- Beta (5Y)
- 1.27
- 52-week high
- $2.88
- 52-week low
- $0.16
- Avg volume (3M)
- —
- Shares outstanding
- 30.44M
- Employees
- 19
- Next earnings
- —
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
- ISIN
- US00901B3033
- Founded
- 1966
- Listed since
- Nov 2, 1995
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| LianMedicalOTCPK: LIAN.Y | $5.52M | $0.05 | -12.45% |
| Alpha Compute CorpNasdaqCM: ALP | $5.27M | $3.40 | -14.36% |
| AquaBounty Technologies, Inc.NasdaqCM: AQB | $5.25M | $1.02 | -5.56% |
| Marvel Biosciences Corp.TSXV: MRVL | $5.22M | CA$0.10 | -13.04% |
| Cardio Diagnostics Holdings, Inc.NasdaqCM: CDIO | $5.00M | $1.69 | -9.63% |
| Plant Advanced Technologies SAENXTPA: ALPAT | $4.96M | €3.94 | -1.01% |
| genXone S.A.WSE: GX1 | $4.90M | zł5.76 | -2.37% |
| Creative Medical Technology Holdings, Inc.NasdaqCM: CELZ | $4.89M | $0.74 | -11.63% |
Figures last refreshed Oct 18, 2026.